DE-W.-L.-GORE
21.1.2019 09:02:07 CET | Business Wire | Press release
W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile allows physicians to perform TEVAR in patients with smaller vessels where access is challenging and aortic anatomy is tortuous, expanding the availability of Gore’s thoracic stent graft to a greater population of patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005042/en/
The GORE® TAG® Conformable Thoracic Stent Graft was modified to reduce the delivery profile of the 31, 37, and 40 mm device diameters by 2 Fr for all lengths. The reduction in profile, through the use of a smaller diameter primary sleeve, is the only change to the device. The stent graft leverages the same predictable outcomes of the time-tested Conformable GORE® TAG® Device, which has established long-term freedom from reintervention (93.1%), low complication rates, with zero migrations, fractures, or compressions.* and a low 2.4% access site complication rate for endovascular treatment of the descending thoracic aorta.** The new profiles also continue to feature the same unique combination of proprietary ePTFE graft material and a fully supported, nested, nitinol stent.
“As the market for TEVAR has continued to expand and evolve, lower profile devices have rapidly emerged with a goal of increased patient applicability, accessibility, trackability and finally reducing access complications for patients with smaller vessels ,” said Professor Boeckler. “It’s reassuring that the new reduced profile sizes of the GORE® TAG® Conformable Thoracic Stent Graft was achieved without changes to the stent graft. Gore’s device is known for its conformability, and the GORE ACTIVE CONTROL System enables me to take full advantage of the conformability by allowing precise placement during TEVAR procedures. The combination of controlled delivery with the trusted stent graft, and now reduced profile for the device, is a significant advancemen t and approaches unmet needs performing TEVAR in my daily practice.”
The new reduced profile devices continue to feature the GORE® ACTIVE CONTROL System, which facilitates optimized wall apposition even in complex anatomies, such as acute aortic angles. Now, the additional reduced profiles on critical sizes needed allow the device to be introduced through a smaller sheath.
“This milestone is one of several that illustrate our continued dedication to innovate our devices for better long-term patient care,” said Erik Davies, vascular global marketing leader at Gore. “We are proud that we were able to reduce the profile of the GORE® TAG® Conformable Thoracic Stent Graft without changing the design of the device. Patients with smaller vessels are now able to receive the same conformable device that has demonstrated trusted and safe performance for the past 20 years. Maintaining the integrity of the device, Gore’s launch of reduced profiles on critical sizes showcases our continued commitment to developing solutions that advance endovascular solutions for diseases of the aorta.”
The GORE® TAG® Conformable Stent Graft with ACTIVE CONTROL System is part of the growing family of endovascular products that share a mission to effectively treat aortic disease, backed by Gore’s highly rated clinical support team and educational offerings. The portfolio of products includes the GORE® EXCLUDER® AAA Endoprosthesis for the treatment of abdominal aortic aneurysms (AAA), as well as the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System , also approved in EU. Together, the GORE EXCLUDER device family is indicated to treat the broadest range of abdominal aortic aneurysms in patients with challenging anatomies. The GORE® EXCLUDER® Iliac Branch Endoprosthesis is approved in EU and is the first FDA-approved, off-the-shelf device for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms, and is indicated for use with the GORE EXCLUDER AAA Endoprosthesis. For potential additions to its branched portfolio, Gore continues to conduct studies on new and novel technologies to treat other aortic disease states.
* Reported outcomes following 5-year-follow-up in FDA PMA clinical
studies.
** Serious adverse events within 30 days of the
procedure. GREAT Post Market Global Registry data collected from 862
patients treated with the Conformable GORE® TAG® Thoracic Endoprosthesis.
MEDICAL PRODUCTS DIVISION
Gore engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. www.goremedical.com
About Gore
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments — from revolutionizing the outerwear industry with GORE-TEX® fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. The company is also known for its strong, team-oriented culture and global recognition from the Great Place to Work® Institute. Headquartered in Newark, Del., Gore employs 9,500 Associates and generates annual revenues of $3.5 billion. www.gore.com
Products listed may not be available in all markets.
GORE
®,
GORE-TEX
®, ACTIVE CONTROL, EXCLUDER
®, and TAG
® are
trademarks of W. L. Gore & Associates.
AX1645-EN1
JANUARY
2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20190121005042/en/
Contact:
Media Contacts Bliss Integrated Communication for Gore Medical Nathan Molinari, 646-846-3210 nmolinari@blissintegrated.com or Liz DeForest, 212-584-5477 liz@blissintegrated.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom